BRPI0612534A8 - derivado de quinolina como agentes antibacterianos - Google Patents
derivado de quinolina como agentes antibacterianosInfo
- Publication number
- BRPI0612534A8 BRPI0612534A8 BRPI0612534A BRPI0612534A BRPI0612534A8 BR PI0612534 A8 BRPI0612534 A8 BR PI0612534A8 BR PI0612534 A BRPI0612534 A BR PI0612534A BR PI0612534 A BRPI0612534 A BR PI0612534A BR PI0612534 A8 BRPI0612534 A8 BR PI0612534A8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- combination
- antibacterial agents
- quinoline derivative
- bacterial infection
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title abstract 2
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 2
- 206010062207 Mycobacterial infection Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- -1 quinoline derivative compound Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
Abstract
uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto. a presente invenção refere-se a um uso de um composto para a produção de um medicamento para o tratamento de uma infecção bacteriana, com a condição de que a infecção bacteriana seja diferente de uma infecção micobacteriana, o referido composto sendo um composto de fórmula (la) ou (lb), um sal de adição de base ou ácido farmaceuticamente aceitável seu, uma forma estereoquimicamente isomérica sua, uma forma tautomérica sua ou uma forma de n-óxido sua. vários desses compostos também são reivindicados como tais. além disso, a combinação dos compostos acima com outros agentes antibacterianos é descrita.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05105769 | 2005-06-28 | ||
| EP05105769.3 | 2005-06-28 | ||
| PCT/EP2006/063556 WO2007000436A1 (en) | 2005-06-28 | 2006-06-26 | Quinoline derivatives as antibacterial agents |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BRPI0612534A2 BRPI0612534A2 (pt) | 2010-11-23 |
| BRPI0612534A8 true BRPI0612534A8 (pt) | 2017-12-26 |
| BRPI0612534B1 BRPI0612534B1 (pt) | 2020-04-22 |
| BRPI0612534B8 BRPI0612534B8 (pt) | 2021-05-25 |
Family
ID=35445742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0612534A BRPI0612534B8 (pt) | 2005-06-28 | 2006-06-26 | uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US20100204270A1 (pt) |
| EP (1) | EP1898910B1 (pt) |
| JP (1) | JP5193859B2 (pt) |
| KR (1) | KR101423229B1 (pt) |
| CN (1) | CN101252928B (pt) |
| AP (1) | AP2733A (pt) |
| AR (1) | AR057654A1 (pt) |
| AU (1) | AU2006263884B2 (pt) |
| BR (1) | BRPI0612534B8 (pt) |
| CA (1) | CA2612623C (pt) |
| CY (1) | CY1118515T1 (pt) |
| DK (1) | DK1898910T3 (pt) |
| EA (1) | EA014163B1 (pt) |
| ES (1) | ES2606772T3 (pt) |
| HK (1) | HK1120734A1 (pt) |
| HR (1) | HRP20161704T1 (pt) |
| HU (1) | HUE031268T2 (pt) |
| IL (1) | IL188394A (pt) |
| JO (1) | JO3270B1 (pt) |
| LT (1) | LT1898910T (pt) |
| ME (1) | ME02690B (pt) |
| MX (1) | MX2008000082A (pt) |
| MY (1) | MY151030A (pt) |
| NO (1) | NO341283B1 (pt) |
| NZ (1) | NZ564339A (pt) |
| PL (1) | PL1898910T3 (pt) |
| PT (1) | PT1898910T (pt) |
| RS (1) | RS55408B1 (pt) |
| SG (1) | SG166799A1 (pt) |
| SI (1) | SI1898910T1 (pt) |
| TW (1) | TWI392494B (pt) |
| UA (1) | UA91549C2 (pt) |
| WO (1) | WO2007000436A1 (pt) |
| ZA (1) | ZA200711149B (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9790186B2 (en) | 2009-07-21 | 2017-10-17 | Trustees Of Dartmouth College | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection |
| ES2576491T3 (es) | 2012-04-27 | 2016-07-07 | Janssen Pharmaceutica, N.V. | Derivados de quinolina antibacterianos |
| MX358506B (es) | 2012-04-27 | 2018-08-22 | Janssen Pharmaceutica Nv | Derivados de quinolina antibacterianos. |
| CN105037497B (zh) * | 2015-03-27 | 2018-06-26 | 中牧实业股份有限公司 | 一种恩拉霉素的提纯方法 |
| WO2017035288A1 (en) * | 2015-08-27 | 2017-03-02 | Trustees Of Dartmouth College | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| DE19937116A1 (de) * | 1999-08-06 | 2001-02-08 | Bayer Ag | Moxifloxacin Kochsalzformulierung |
| DK2301544T3 (da) * | 2002-07-25 | 2013-01-02 | Janssen Pharmaceutica Nv | Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer |
| MXPA06013888A (es) * | 2004-05-28 | 2007-01-26 | Janssen Pharmaceutica Nv | Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos. |
| EE05394B1 (et) * | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
-
2006
- 2006-06-25 JO JOP/2006/0189A patent/JO3270B1/ar active
- 2006-06-26 WO PCT/EP2006/063556 patent/WO2007000436A1/en active Application Filing
- 2006-06-26 MX MX2008000082A patent/MX2008000082A/es active IP Right Grant
- 2006-06-26 PL PL06763891T patent/PL1898910T3/pl unknown
- 2006-06-26 EA EA200800152A patent/EA014163B1/ru unknown
- 2006-06-26 ES ES06763891.6T patent/ES2606772T3/es active Active
- 2006-06-26 AU AU2006263884A patent/AU2006263884B2/en active Active
- 2006-06-26 PT PT67638916T patent/PT1898910T/pt unknown
- 2006-06-26 US US11/917,923 patent/US20100204270A1/en not_active Abandoned
- 2006-06-26 CN CN2006800313527A patent/CN101252928B/zh active Active
- 2006-06-26 LT LTEP06763891.6T patent/LT1898910T/lt unknown
- 2006-06-26 SI SI200632126A patent/SI1898910T1/sl unknown
- 2006-06-26 CA CA2612623A patent/CA2612623C/en active Active
- 2006-06-26 JP JP2008518812A patent/JP5193859B2/ja active Active
- 2006-06-26 HU HUE06763891A patent/HUE031268T2/en unknown
- 2006-06-26 BR BRPI0612534A patent/BRPI0612534B8/pt not_active IP Right Cessation
- 2006-06-26 EP EP06763891.6A patent/EP1898910B1/en active Active
- 2006-06-26 RS RS20161121A patent/RS55408B1/sr unknown
- 2006-06-26 ME MEP-2016-291A patent/ME02690B/me unknown
- 2006-06-26 SG SG201007977-0A patent/SG166799A1/en unknown
- 2006-06-26 UA UAA200714716A patent/UA91549C2/ru unknown
- 2006-06-26 DK DK06763891.6T patent/DK1898910T3/en active
- 2006-06-26 KR KR1020087002248A patent/KR101423229B1/ko active IP Right Grant
- 2006-06-26 AP AP2008004300A patent/AP2733A/xx active
- 2006-06-26 NZ NZ564339A patent/NZ564339A/en unknown
- 2006-06-27 AR ARP060102760A patent/AR057654A1/es unknown
- 2006-06-27 MY MYPI20063045 patent/MY151030A/en unknown
- 2006-06-27 TW TW095123051A patent/TWI392494B/zh active
-
2007
- 2007-12-20 ZA ZA200711149A patent/ZA200711149B/xx unknown
- 2007-12-25 IL IL188394A patent/IL188394A/en active IP Right Grant
-
2008
- 2008-01-25 NO NO20080481A patent/NO341283B1/no not_active IP Right Cessation
- 2008-11-18 HK HK08112595.6A patent/HK1120734A1/xx unknown
-
2012
- 2012-08-07 US US13/568,597 patent/US20130030017A1/en not_active Abandoned
-
2016
- 2016-12-13 HR HRP20161704TT patent/HRP20161704T1/hr unknown
- 2016-12-20 CY CY20161101322T patent/CY1118515T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0720220B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo | |
| BRPI0610850A2 (pt) | derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados | |
| UA94901C2 (ru) | Антибактериальные производные пиперидина | |
| AR107864A1 (es) | ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS | |
| BRPI0510414A (pt) | uso de derivados de quinolina substituìdos para o tratamento de doenças micobacterianas resistentes a fármacos | |
| BR112015016315A2 (pt) | fluoro-[1,3]oxazinas como inibidores de bace1 | |
| CY1113269T1 (el) | Παραγωγα ινδαζολυλ αμιδιου για τη θεραπευτικη αγωγη διαταραχων διαμεσολαβουμενων υπο υποδοχεα γλυκοκορτικοειδων | |
| BR112012017269A2 (pt) | compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos | |
| UY30759A1 (es) | Compuestos quimicos | |
| BRPI0412291A (pt) | antagonistas duplos de nka/nk3 para o tratamento de esquizofrenia | |
| EA201170249A1 (ru) | 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ | |
| DE60331056D1 (de) | 6-11 bicyclische ketolidderivate | |
| BRPI0614493B8 (pt) | uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, processo para a preparação de um composto e o referido composto | |
| EA200970081A1 (ru) | Соединения, обладающие потенциирующим действием в отношении активности этионамида, и их применения | |
| BR112014028954A2 (pt) | amidas de n-piridinila substituídas no anel como inibidores da quinase | |
| BR112014002958A2 (pt) | "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com piperidinila antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso". | |
| BRPI0921705B8 (pt) | composição farmacêutica antimicrobiana e seu uso | |
| BR112015019412A2 (pt) | inibidores de bace1 | |
| BRPI0719920B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário | |
| BRPI0613999B8 (pt) | uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto | |
| ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
| BR112014003063A2 (pt) | "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com ciclopenta[c]pirrol antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso". | |
| BRPI0614122A8 (pt) | composto derivado de quinolina, composição farmacêutica e uso do referido composto | |
| EA201992090A1 (ru) | ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| BRPI0612534A8 (pt) | derivado de quinolina como agentes antibacterianos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/04/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/06/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |